Antibiotic Resistance Market Size, Trends & Growth Report by 2034

Market Segmentation

Antibiotic Resistance Market, By Disease (2022-2034)

cUTI (Complicated Urinary Tract Infections)
CDI (Clostridioides difficile Infection)
ABSSSI (Acute bacterial skin and skin structure infections)
HABP (Hospital-acquired bacterial pneumonia)
CABP (Community-acquired pneumonia)
cIAI (Complicated intra-abdominal infection)
BSI (Bloodstream infection)

Antibiotic Resistance Market, By Pathogen (2022-2034)

coli
pneumoniae
aeruginosa
aureus
baumannii
influenzae
difficile
faecium

Antibiotic Resistance Market, By Drug Class (2022-2034)

Oxazolidinones
Lipoglycopeptides
Tetracyclines
Combination therapies
Cephalosporins
Others

Antibiotic Resistance Market, By Mechanism of Action (2022-2034)

Protein Synthesis Inhibitors
Cell Wall Synthesis Inhibitors
RNA Synthesis Inhibitors
DNA Synthesis Inhibitors
Others

Antibiotic Resistance Market, By Distribution Channel (2022-2034)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Regional Antibiotic Resistance Market

North America
1. North America Antibiotic Resistance Market, By Disease
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
2. North America Antibiotic Resistance Market, By Pathogen
  1. coli
  2. pneumoniae
  3. aeruginosa
  4. aureus
  5. baumannii
  6. influenzae
  7. difficile
  8. faecium
3. North America Antibiotic Resistance Market, By Drug Class
  1. Oxazolidinones
  2. Lipoglycopeptides
  3. Tetracyclines
  4. Combination therapies
  5. Cephalosporins
  6. Others
4. North America Antibiotic Resistance Market, By Mechanism of Action
  1. Protein Synthesis Inhibitors
  2. Cell Wall Synthesis Inhibitors
  3. RNA Synthesis Inhibitors
  4. DNA Synthesis Inhibitors
  5. Others
5. North America Antibiotic Resistance Market, By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
6. U.S.
  1. U.S. Antibiotic Resistance Market, By Disease
    1. cUTI (Complicated Urinary Tract Infections)
    2. CDI (Clostridioides difficile Infection)
    3. ABSSSI (Acute bacterial skin and skin structure infections)
    4. HABP (Hospital-acquired bacterial pneumonia)
    5. CABP (Community-acquired pneumonia)
    6. cIAI (Complicated intra-abdominal infection)
    7. BSI (Bloodstream infection)
  2. U.S. Antibiotic Resistance Market, By Pathogen
    1. coli
    2. pneumoniae
    3. aeruginosa
    4. aureus
    5. baumannii
    6. influenzae
    7. difficile
    8. faecium
  3. U.S. Antibiotic Resistance Market, By Drug Class
    1. Oxazolidinones
    2. Lipoglycopeptides
    3. Tetracyclines
    4. Combination therapies
    5. Cephalosporins
    6. Others
  4. U.S. Antibiotic Resistance Market, By Mechanism of Action
    1. Protein Synthesis Inhibitors
    2. Cell Wall Synthesis Inhibitors
    3. RNA Synthesis Inhibitors
    4. DNA Synthesis Inhibitors
    5. Others
  5. U.S. Antibiotic Resistance Market, By Distribution Channel
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
7. Canada
Europe
1. Europe Antibiotic Resistance Market, By Disease
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
2. Europe Antibiotic Resistance Market, By Pathogen
  1. coli
  2. pneumoniae
  3. aeruginosa
  4. aureus
  5. baumannii
  6. influenzae
  7. difficile
  8. faecium
3. Europe Antibiotic Resistance Market, By Drug Class
  1. Oxazolidinones
  2. Lipoglycopeptides
  3. Tetracyclines
  4. Combination therapies
  5. Cephalosporins
  6. Others
4. Europe Antibiotic Resistance Market, By Mechanism of Action
  1. Protein Synthesis Inhibitors
  2. Cell Wall Synthesis Inhibitors
  3. RNA Synthesis Inhibitors
  4. DNA Synthesis Inhibitors
  5. Others
5. Europe Antibiotic Resistance Market, By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
6. U.K.
  1. U.K. Antibiotic Resistance Market, By Disease
    1. cUTI (Complicated Urinary Tract Infections)
    2. CDI (Clostridioides difficile Infection)
    3. ABSSSI (Acute bacterial skin and skin structure infections)
    4. HABP (Hospital-acquired bacterial pneumonia)
    5. CABP (Community-acquired pneumonia)
    6. cIAI (Complicated intra-abdominal infection)
    7. BSI (Bloodstream infection)
  2. U.K. Antibiotic Resistance Market, By Pathogen
    1. coli
    2. pneumoniae
    3. aeruginosa
    4. aureus
    5. baumannii
    6. influenzae
    7. difficile
    8. faecium
  3. U.K. Antibiotic Resistance Market, By Drug Class
    1. Oxazolidinones
    2. Lipoglycopeptides
    3. Tetracyclines
    4. Combination therapies
    5. Cephalosporins
    6. Others
  4. U.K. Antibiotic Resistance Market, By Mechanism of Action
    1. Protein Synthesis Inhibitors
    2. Cell Wall Synthesis Inhibitors
    3. RNA Synthesis Inhibitors
    4. DNA Synthesis Inhibitors
    5. Others
  5. U.K. Antibiotic Resistance Market, By Distribution Channel
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
7. Germany
8. France
9. Spain
10. Italy
11. Russia
12. Nordic
13. Benelux
14. Rest of Europe
APAC
1. APAC Antibiotic Resistance Market, By Disease
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
2. APAC Antibiotic Resistance Market, By Pathogen
  1. coli
  2. pneumoniae
  3. aeruginosa
  4. aureus
  5. baumannii
  6. influenzae
  7. difficile
  8. faecium
3. APAC Antibiotic Resistance Market, By Drug Class
  1. Oxazolidinones
  2. Lipoglycopeptides
  3. Tetracyclines
  4. Combination therapies
  5. Cephalosporins
  6. Others
4. APAC Antibiotic Resistance Market, By Mechanism of Action
  1. Protein Synthesis Inhibitors
  2. Cell Wall Synthesis Inhibitors
  3. RNA Synthesis Inhibitors
  4. DNA Synthesis Inhibitors
  5. Others
5. APAC Antibiotic Resistance Market, By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
6. China
  1. China Antibiotic Resistance Market, By Disease
    1. cUTI (Complicated Urinary Tract Infections)
    2. CDI (Clostridioides difficile Infection)
    3. ABSSSI (Acute bacterial skin and skin structure infections)
    4. HABP (Hospital-acquired bacterial pneumonia)
    5. CABP (Community-acquired pneumonia)
    6. cIAI (Complicated intra-abdominal infection)
    7. BSI (Bloodstream infection)
  2. China Antibiotic Resistance Market, By Pathogen
    1. coli
    2. pneumoniae
    3. aeruginosa
    4. aureus
    5. baumannii
    6. influenzae
    7. difficile
    8. faecium
  3. China Antibiotic Resistance Market, By Drug Class
    1. Oxazolidinones
    2. Lipoglycopeptides
    3. Tetracyclines
    4. Combination therapies
    5. Cephalosporins
    6. Others
  4. China Antibiotic Resistance Market, By Mechanism of Action
    1. Protein Synthesis Inhibitors
    2. Cell Wall Synthesis Inhibitors
    3. RNA Synthesis Inhibitors
    4. DNA Synthesis Inhibitors
    5. Others
  5. China Antibiotic Resistance Market, By Distribution Channel
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
7. Korea
8. Japan
9. India
10. Australia
11. Taiwan
12. South East Asia
13. Rest of Asia-Pacific
Middle East and Africa
1. Middle East and Africa Antibiotic Resistance Market, By Disease
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
2. Middle East and Africa Antibiotic Resistance Market, By Pathogen
  1. coli
  2. pneumoniae
  3. aeruginosa
  4. aureus
  5. baumannii
  6. influenzae
  7. difficile
  8. faecium
3. Middle East and Africa Antibiotic Resistance Market, By Drug Class
  1. Oxazolidinones
  2. Lipoglycopeptides
  3. Tetracyclines
  4. Combination therapies
  5. Cephalosporins
  6. Others
4. Middle East and Africa Antibiotic Resistance Market, By Mechanism of Action
  1. Protein Synthesis Inhibitors
  2. Cell Wall Synthesis Inhibitors
  3. RNA Synthesis Inhibitors
  4. DNA Synthesis Inhibitors
  5. Others
5. Middle East and Africa Antibiotic Resistance Market, By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
6. UAE
  1. UAE Antibiotic Resistance Market, By Disease
    1. cUTI (Complicated Urinary Tract Infections)
    2. CDI (Clostridioides difficile Infection)
    3. ABSSSI (Acute bacterial skin and skin structure infections)
    4. HABP (Hospital-acquired bacterial pneumonia)
    5. CABP (Community-acquired pneumonia)
    6. cIAI (Complicated intra-abdominal infection)
    7. BSI (Bloodstream infection)
  2. UAE Antibiotic Resistance Market, By Pathogen
    1. coli
    2. pneumoniae
    3. aeruginosa
    4. aureus
    5. baumannii
    6. influenzae
    7. difficile
    8. faecium
  3. UAE Antibiotic Resistance Market, By Drug Class
    1. Oxazolidinones
    2. Lipoglycopeptides
    3. Tetracyclines
    4. Combination therapies
    5. Cephalosporins
    6. Others
  4. UAE Antibiotic Resistance Market, By Mechanism of Action
    1. Protein Synthesis Inhibitors
    2. Cell Wall Synthesis Inhibitors
    3. RNA Synthesis Inhibitors
    4. DNA Synthesis Inhibitors
    5. Others
  5. UAE Antibiotic Resistance Market, By Distribution Channel
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
7. Turkey
8. Saudi Arabia
9. South Africa
10. Egypt
11. Nigeria
12. Rest of MEA
LATAM
1. LATAM Antibiotic Resistance Market, By Disease
  1. cUTI (Complicated Urinary Tract Infections)
  2. CDI (Clostridioides difficile Infection)
  3. ABSSSI (Acute bacterial skin and skin structure infections)
  4. HABP (Hospital-acquired bacterial pneumonia)
  5. CABP (Community-acquired pneumonia)
  6. cIAI (Complicated intra-abdominal infection)
  7. BSI (Bloodstream infection)
2. LATAM Antibiotic Resistance Market, By Pathogen
  1. coli
  2. pneumoniae
  3. aeruginosa
  4. aureus
  5. baumannii
  6. influenzae
  7. difficile
  8. faecium
3. LATAM Antibiotic Resistance Market, By Drug Class
  1. Oxazolidinones
  2. Lipoglycopeptides
  3. Tetracyclines
  4. Combination therapies
  5. Cephalosporins
  6. Others
4. LATAM Antibiotic Resistance Market, By Mechanism of Action
  1. Protein Synthesis Inhibitors
  2. Cell Wall Synthesis Inhibitors
  3. RNA Synthesis Inhibitors
  4. DNA Synthesis Inhibitors
  5. Others
5. LATAM Antibiotic Resistance Market, By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
6. Brazil
  1. Brazil Antibiotic Resistance Market, By Disease
    1. cUTI (Complicated Urinary Tract Infections)
    2. CDI (Clostridioides difficile Infection)
    3. ABSSSI (Acute bacterial skin and skin structure infections)
    4. HABP (Hospital-acquired bacterial pneumonia)
    5. CABP (Community-acquired pneumonia)
    6. cIAI (Complicated intra-abdominal infection)
    7. BSI (Bloodstream infection)
  2. Brazil Antibiotic Resistance Market, By Pathogen
    1. coli
    2. pneumoniae
    3. aeruginosa
    4. aureus
    5. baumannii
    6. influenzae
    7. difficile
    8. faecium
  3. Brazil Antibiotic Resistance Market, By Drug Class
    1. Oxazolidinones
    2. Lipoglycopeptides
    3. Tetracyclines
    4. Combination therapies
    5. Cephalosporins
    6. Others
  4. Brazil Antibiotic Resistance Market, By Mechanism of Action
    1. Protein Synthesis Inhibitors
    2. Cell Wall Synthesis Inhibitors
    3. RNA Synthesis Inhibitors
    4. DNA Synthesis Inhibitors
    5. Others
  5. Brazil Antibiotic Resistance Market, By Distribution Channel
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
7. Mexico
8. Argentina
9. Chile
10. Colombia
11. Rest of LATAM